1. A motor for a personal care appliance, comprising:
a stator assembly portion driven by a drive assembly which includes a source of alternating current;
an armature portion responsive to the stator action to move through a path;
a mounting member affixed to a housing portion of the personal care appliance;
a flexure assembly connected between the armature and the mounting member, such that the armature in operation moves in an arcuate path about a pivot point located apart from and between the mounting member and the armature; and
a workpiece assembly mounted to and extending from the armature but not connected directly to the pivot point, such that the workpiece oscillates through a desired angle.
2. The motor of claim 1, wherein the desired angle is approximately within the range of +3\xb0 to +15\xb0.
3. The motor of claim 1, wherein the flexure assembly includes at least two separate flexure members which cross each other between the mounting member and the armature at a point removed from both the mounting member and the armature, wherein the armature moves about a pivot point approximately where the flexure members cross.
4. The motor of claim 1, wherein the workpiece is a skin brush.
5. The motor of claim 1, wherein the workpiece assembly includes a mounting arm which is mounted to and extends from the armature, and wherein the workpiece is mounted upon a free end of the mounting arm.
6. The motor of claim 1, wherein the mounting arm and the armature are arranged so that the workpiece rotates about an axis approximately at right angles to the longitudinal axis of the appliance.
7. The motor of claim 1, wherein the mounting arm and the armature are arranged so that the workpiece rotates about an axis which is approximately parallel to the longitudinal axis of the appliance.
8. The motor of claim 1, wherein the stator portion includes an E-core member having a center leg and two outer legs, wherein the armature portion includes a backiron which has two spaced magnets mounted thereon with the magnetic poles thereof aligned in opposing directions, and wherein the width of the center leg of the E-core member is approximately 0.50-0.60 times the width of the faces of the magnets, the width of the outer legs is approximately 0.90-1.10 times the width of the faces of the magnets, the width of the distance between the center leg and the two outer legs, respectively, is 1.95-2.20 times the width of the magnet face and the length of the center leg is 1.95-2.15 times the width of said distance between the center leg and the two outer legs.
9. The motor of claim 8, wherein the distance between the centers of the magnets is 2.40-2.60 times the width of the faces of the magnets and wherein the magnets are positioned at an angle in the range of 18-22\xb0 relative to a line passing through a midpoint of the backiron and said pivot point.
10. A personal care appliance, comprising:
an appliance housing;
a drive assembly which includes a source of alternating current;
a motor which includes a stator assembly portion driven by the alternating current and an armature portion responsive to the stator action to move through a path;
a mounting assembly affixed to the housing;
a flexure assembly connected between the armature and the mounting member, such that the armature moves in an arcuate path about a pivot point located apart from and between the mounting member and the armature; and
a workpiece assembly which includes a mounting arm mounted to and extending from the armature and a skin brush mounted on a free end of the mounting member, wherein the workpiece assembly is not connected directly to the pivot point and wherein the mounting arm is configured such that the workpiece oscillates about the pivot point through a desired angle.
11. The appliance of claim 8, wherein the desired angle of oscillation of the workpiece is approximately within the range of +3\xb0 to +15\xb0.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. Pharmaceutical composition for topical administration comprising a mixture of:
a) hyaluronic acid or salts thereof selected from the group consisting of sodium and potassium; and
b) a bradykinin B2 receptor antagonist together with pharmaceutically acceptable carriers and excipients, wherein:
(i) the hyaluronic acid is in polymer form with a mean MW between 0.5 and 10 million daltons,
(ii) the hyaluronic acid is in an amount of 1-100 mg per dose,
(iii) the bradykinin B2 receptor antagonist is selected from the group consisting of compounds of formula (I)
wherein
R is hydrogen or methyl
W represents a simple bond or an O atom
n=3, 4
X is hydrogen or a \u2014NR1R2 amino group in which R1 and R2 can be independently of one another hydrogen or a group selected from methyl, ethyl n-propyl, isopropyl, and
Y is a quaternary ammonium (\u2014NR3R4R5)+A\u2212 in which R3, R4, R5 can be independently of one another methyl, ethyl n-propyl, isopropyl, butyl, isobutyl, n-pentyl and A\u2212 is an anion of a pharmaceutically acceptable acid;
the pharmacologically acceptable salts, enantiomers and enantiomeric mixtures thereof,
(iv) the bradykinin B2 receptor antagonist is in an amount of between 5.7\xd710\u22125 and 2.3\xd710\u22122 mMoles per dose, and
(v) the composition is in the form of an intra-articular or intrabursal injectable solution or a transdermal form selected from cream, gel or patch.
2. Pharmaceutical composition as claimed in claim 1, wherein the bradykinin B2 receptor antagonist is the compound of general formula (I): (4-(S)-amino-5-(4-{4-2,4-dichloro-3-(2,4-dimethyl-quinoline-8-yl oxymethyl)-benzenesulphonylamino-tetrahydro-pyran-4-carbonyl}-piperazin-1-yl)-5-oxo-pentyl)-trimethyl-ammonium in salified form with ions formally deriving from an acid selected from hydrochloric, acetic, sulphuric, trifluoroacetic, methanesulphonic, succinic and edetic acids.
3. Pharmaceutical composition as claimed in claim 2, wherein the compound (4-(S)-amino-5 (4-{4-2,4-dichloro-3-(2,4-dimethyl-quinoline-8-yl oxymethyl)-benzenesulphonylamino-tetrahydro-pyran-4-carbonyl}-piperazin-1-yl)-5-oxo-pentyl)-trimethyl-ammonium is in the form of chloride dihydrochloride.
4. Pharmaceutical composition as claimed in claim 1, wherein the amount of hyaluronic acid per dose is 5-20 mg.
5. Pharmaceutical composition as claimed in claim 1, wherein the mean MW of the hyaluronic acid ranges between 4 and 9 million daltons.
6. Pharmaceutical composition as claimed in claim 5, wherein the mean MW of the hyaluronic acid ranges between 5 and 8 million daltons.
7. Pharmaceutical composition as claimed in claim 1, wherein the amount of bradykinin B2 receptor antagonist is between 1.1\xd710\u22124 and 1.1\xd710\u22122 mMoles per dose.
8. Pharmaceutical composition as claimed in claim 7, wherein the amount of bradykinin B2 receptor antagonist is between 2.9\xd710\u22124 and 5.7\xd710\u22123 mmols per dose.
9. Pharmaceutical composition as claimed in claim 1, wherein the bradykinin antagonist is in a solid form selected from crystalline, amorphous or lyophilised, to be dissolved before use in a solution containing hyaluronic acid so as to constitute the intra-articular or intrabursal injectable solution.
10. Pharmaceutical composition as claimed in claim 1, also containing a buffer selected from phosphate or citrate.
11. Pharmaceutical composition as claimed in claim 1, also containing sodium chloride as isotonicity regulator.
12. Pharmaceutical composition as claimed in claim 1, also containing sodium edetate as preservative and chelating agent.
13. Pharmaceutical composition as claimed in claim 1, wherein said amount of bradykinin B2 receptor antagonist corresponds to an amount of 0.05 to 20 mg per dose of (4-(S)-amino-5-(4-{4-2,4-dichloro-3-(2,4-dimethyl-quinoline-8-yl oxymethyl)-benzenesulphonylamino-tetrahydro-pyran-4-carbonyl}-piperazin-1-yl)-5-oxo-pentyl)-trimethyl-ammonium chloride dihydrochloride.
14. Pharmaceutical composition as claimed in claim 7, wherein said amount of bradykinin B2 receptor antagonist corresponds to an amount of 0.1 to 10 mg per dose of (4-(S)-amino-5-(4-{4-2,4-dichloro-3-(2,4-dimethyl-quinoline-8-yl oxymethyl)-benzenesulphonylamino-tetrahydro-pyran-4-carbonyl}-piperazin-1-yl)-5-oxo-pentyl)-trimethyl-ammonium chloride dihydrochloride.
15. Pharmaceutical composition as claimed in claim 8, wherein said amount of bradykinin B2 receptor antagonist corresponds to an amount of 0.25 to 5 mg per dose of (4-(S)-amino-5-(4-{4-2,4-dichloro-3-(2,4-dimethyl-quinoline-8-yl oxymethyl)-benzenesulphonylamino-tetra-hydro-pyran-4-carbonyl}-piperazin-1-yl)-5-oxo-pentyl)-trimethyl-ammonium chloride dihydrochloride.